Tilrekimig in adults and teens with eczema too severe for standard creams

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 study tests tilrekimig against a placebo in a 2:1 ratio over 24 weeks, with the last dose given at week 20. Participants are adults and adolescents with chronic, moderate-to-severe atopic dermatitis who have not responded adequately to standard topical treatments. The study evaluates safety and how well tilrekimig works when combined with medicated creams, under careful monitoring. Sites are in Alabama, Arizona, and California, led by Pfizer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants 12 years of age or older
* Must meet the following AD criteria:

  1. Clinical diagnosis of chronic atopic dermatitis (also known as atopic eczema) for at least 12 months prior to Day 1
  2. An inadequate response to standard of care treatments {eg, at least medium potency topical corticosteroids (TCS)} consistent with AD treatment guidelines
  3. Moderate-to-severe eczema for at least 1 year
* Adolescent participants must be up to date on immunizations per local guidance.

Exclusion Criteria:

* Clinically Significant Autoimmune Disease
* Significant Infection History or Active Infection
* Known or Suspected Immunodeficiency/Immunosuppression
* Significant psychiatric illness or suicidality
* Clinically significant hepatic, renal, or hematologic abnormalities

Where it's running

• Northridge Clinical Trials
  Northridge, California, United States Recruiting
• University Clinical Trials, Inc
  San Diego, California, United States Recruiting
• Pediatric Skin Research
  Miami, Florida, United States Recruiting
• AllerVie Clinical Research
  Panama City, Florida, United States Recruiting
• GCP Research , Global Clinical Professionals
  St. Petersburg, Florida, United States Recruiting
• Marietta Dermatology Clinical Research, Inc.
  Marietta, Georgia, United States Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• Nocturnal ScratchSense ring: test of automatic scratch detection in adults with itchy skin

  This study tests whether the Replior ScratchSense ring can accurately detect and measure nighttime scratching in adults with itchy skin conditions.

  Recruiting Replior AB · Grenoble · NCT07909967

• ADBest TREAT Registry for adults with atopic dermatitis

  A registry in Germany is collecting real-world data from adults with atopic dermatitis to see how treatments are used and how the disease affects quality of life.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg · NCT07904546

• How lebrikizumab affects the skin microbiome and mycobiome in adults with atopic dermatitis

  This study looks at whether lebrikizumab changes the skin bacteria, fungi, and specifically Staphylococcus species, in adults with moderate-to-severe atopic dermatitis.

  Recruiting University Hospital Bispebjerg and Frederiksberg · Copenhagen · NCT07807228

• QX-4533 safety study in healthy volunteers and people with moderate-to-severe atopic dermatitis

  This study tests the safety and tolerability of QX-4533, given as a pill, in healthy adults and in patients with moderate-to-severe atopic dermatitis to see how the drug behaves in the body and what side effects may occur.

  Recruiting Phase 1 QuantX Biosciences US Inc. · Shanghai, Shanghai Municipality · NCT07800104

• Tilrekimig for moderate-to-severe eczema in teens and adults

  A 52-week study will test tilrekimig against dupilumab and a placebo to see if it helps people 12 and older with moderate-to-severe atopic dermatitis.

  Recruiting at 31 sites Phase 3 Pfizer · Birmingham, Alabama and 49 other locations · NCT07783425

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.